Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare $(MHLW.SI)$ has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide $(CNP)$ action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.